Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis

Erythropoiesis-stimulating agents (ESAs) are approved to treat anemia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. ESAs reduce transfusion rates, but some clinical studies suggest that ESAs may reduce survival or increase disease progression. This study-level me...

Descripción completa

Detalles Bibliográficos
Autores principales: Hedenus, Michael, Österborg, Anders, Tomita, Dianne, Bohac, Chet, Coiffier, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2012
Materias:
Original Article: Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490475/
https://www.ncbi.nlm.nih.gov/pubmed/22497574
http://dx.doi.org/10.3109/10428194.2012.684347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490475/
https://www.ncbi.nlm.nih.gov/pubmed/22497574
http://dx.doi.org/10.3109/10428194.2012.684347

Ejemplares similares